Haldol (Haloperidol)

Haldol is indicated for several psychiatric disorders where rapid symptom control is needed. It is commonly prescribed in acute care settings and may be used as part of a broader treatment plan.

• Management of schizophrenia, particularly during acute exacerbations.
• Treatment of acute psychosis associated with mood disorders.
• Control of manic episodes in bipolar disorder.
• Reduction of severe tics in Tourette syndrome.
• Adjunctive therapy for agitation in patients with delirium.

Haloperidol can cause a range of side effects that vary in frequency and severity.

Common

• Drowsiness or sedation, especially after injection.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.
• Blurred vision or difficulty focusing.

Serious

• Neuroleptic malignant syndrome, a rare but life‑threatening reaction.
• Tardive dyskinesia, characterized by involuntary movements.
• Significant cardiac arrhythmias, including QT prolongation.
• Severe hypotension or orthostatic dizziness.
• Hyperprolactinemia leading to hormonal disturbances.

Before initiating Haldol, clinicians should evaluate patient history and monitor for potential risks.

• Assess for cardiovascular disease, as haloperidol may affect heart rhythm.
• Review any history of movement disorders or extrapyramidal symptoms.
• Use caution in patients with liver or kidney impairment.
• Monitor for signs of neuroleptic malignant syndrome during treatment.
• Evaluate pregnancy and breastfeeding status, as safety data are limited.
• Adjust dosage in elderly patients to reduce fall risk.

Haloperidol may interact with other medications, influencing its efficacy and safety profile.

Avoid

• Concurrent use with other dopamine antagonists, which can increase extrapyramidal effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole) that raise haloperidol plasma levels.
• Medications that prolong the QT interval, such as certain antiarrhythmics.

Use with caution

• Other antipsychotics or mood stabilizers, requiring close monitoring.
• CNS depressants, including benzodiazepines and opioids, which may enhance sedation.
• Anticholinergic agents that could mask early signs of extrapyramidal symptoms.